An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer-Reference-Cited by-同舟云学术

An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer

Published:2017-05 Issue:5 Volume:12 Page:791-803
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Karasaki Takahiro,Nagayama Kazuhiro,Kuwano Hideki,Nitadori Jun-ichi,Sato Masaaki,Anraku Masaki,Hosoi Akihiro,Matsushita Hirokazu,Morishita Yasuyuki,Kashiwabara Kosuke,Takazawa Masaki,Ohara Osamu,Kakimi Kazuhiro,Nakajima Jun

Funder

Promotion of Science KAKENHI

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma;Advanced Science;2024-07-08

2. The impact of, and expectations for, lipid nanoparticle technology: From cellular targeting to organelle targeting;Journal of Controlled Release;2024-06

3. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial;Nature Medicine;2024-05-14

4. Construction of an immune-related gene prognostic model with experimental validation and analysis of immune cell infiltration in lung adenocarcinoma;Oncology Letters;2024-05-01

5. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments;Cancer Science;2024-03-25